DNLI (Denali Therapeutics) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DNLI Denali Therapeutics Inc DNLI
33 GF Score
Price $25.69
! 6 Warning Signs
View Full Analysis

What is Denali Therapeutics FFO per Share?

FFO per Share only applies to REITs.

DNLI
33GF Score
Denali Therapeutics Inc DNLI
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Denali Therapeutics Business Description

Other Exchanges 4DN:GermanyD2NL34:Brazil
Address 161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
33GF Score

Get the complete analysis for DNLI

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.69
Price